ES2615521T3 - Composiciones que contienen PUFA y métodos de uso de las mismas - Google Patents
Composiciones que contienen PUFA y métodos de uso de las mismas Download PDFInfo
- Publication number
- ES2615521T3 ES2615521T3 ES06770862.8T ES06770862T ES2615521T3 ES 2615521 T3 ES2615521 T3 ES 2615521T3 ES 06770862 T ES06770862 T ES 06770862T ES 2615521 T3 ES2615521 T3 ES 2615521T3
- Authority
- ES
- Spain
- Prior art keywords
- another embodiment
- day
- dosage
- approximately
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract description 18
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract description 29
- 229940045145 uridine Drugs 0.000 abstract description 15
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract description 14
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract description 14
- 229960001231 choline Drugs 0.000 abstract description 9
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract description 9
- 239000004381 Choline salt Substances 0.000 abstract description 5
- 235000019417 choline salt Nutrition 0.000 abstract description 5
- 150000003248 quinolines Chemical class 0.000 abstract description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract description 3
- 208000023105 Huntington disease Diseases 0.000 abstract description 3
- 208000009829 Lewy Body Disease Diseases 0.000 abstract description 3
- 201000002832 Lewy body dementia Diseases 0.000 abstract description 3
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 description 26
- 230000015572 biosynthetic process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 11
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- 229940012843 omega-3 fatty acid Drugs 0.000 description 8
- 206010014476 Elevated cholesterol Diseases 0.000 description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 description 7
- 239000006014 omega-3 oil Substances 0.000 description 7
- 210000004958 brain cell Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 5
- 229940033080 omega-6 fatty acid Drugs 0.000 description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- -1 DHA fatty acid Chemical class 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006790 cellular biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicinal Preparation (AREA)
- Fertilizers (AREA)
- Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68335205P | 2005-05-23 | 2005-05-23 | |
| US683352P | 2005-05-23 | ||
| US71607705P | 2005-09-13 | 2005-09-13 | |
| US716077P | 2005-09-13 | ||
| US75505806P | 2006-01-03 | 2006-01-03 | |
| US755058P | 2006-01-03 | ||
| US76175306P | 2006-01-25 | 2006-01-25 | |
| US761753P | 2006-01-25 | ||
| PCT/US2006/019766 WO2006127620A2 (en) | 2005-05-23 | 2006-05-23 | Compositions containing pufa and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2615521T3 true ES2615521T3 (es) | 2017-06-07 |
Family
ID=37452701
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06770862.8T Active ES2615521T3 (es) | 2005-05-23 | 2006-05-23 | Composiciones que contienen PUFA y métodos de uso de las mismas |
| ES06770871T Active ES2624702T5 (es) | 2005-05-23 | 2006-05-23 | Composiciones que contienen PUFA y/o uridina y métodos para su uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06770871T Active ES2624702T5 (es) | 2005-05-23 | 2006-05-23 | Composiciones que contienen PUFA y/o uridina y métodos para su uso |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10086009B2 (https=) |
| EP (3) | EP1888081B1 (https=) |
| JP (3) | JP5566603B2 (https=) |
| CN (1) | CN105663151A (https=) |
| AU (2) | AU2006251569B2 (https=) |
| BR (2) | BRPI0613303A8 (https=) |
| CA (2) | CA2645645C (https=) |
| DK (1) | DK1888081T3 (https=) |
| ES (2) | ES2615521T3 (https=) |
| HU (1) | HUE031206T2 (https=) |
| NZ (3) | NZ563659A (https=) |
| PL (1) | PL1888081T3 (https=) |
| PT (1) | PT1888081T (https=) |
| RU (1) | RU2603470C2 (https=) |
| WO (2) | WO2006127627A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| BR0315942A (pt) * | 2002-11-27 | 2005-10-04 | Dmi Biosciences Inc | Tratamento de doenças e condições mediadas pelo aumento de fosforilação |
| EP1888081B1 (en) * | 2005-05-23 | 2016-12-28 | Massachusetts Institute of Technology | Compositions containing pufa and methods of use thereof |
| BRPI0613358A8 (pt) * | 2005-07-08 | 2017-12-26 | Dsm Ip Assets Bv | ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência |
| EP1951308B1 (de) * | 2005-11-25 | 2013-02-20 | Gisela Susilo | Kombinationspräparate enthaltend physiologische zellmembran-bestandteile, einschliesslich phosphatidylserin, cholin und ein pyrimidinnukleos/tid |
| KR20090097945A (ko) * | 2006-12-28 | 2009-09-16 | 메이지 데어리즈 코포레이션 | 젖 유래 인지질을 함유하는 유유아 뇌발달 촉진제 및 그것을 함유하는 식품 조성물 |
| WO2009002145A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| ES2808406T3 (es) * | 2007-06-26 | 2021-02-26 | Nutricia Nv | Mejora de la memoria en sujetos con un mini examen del estado mental de 24-26 |
| WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| BRPI0817387A2 (pt) * | 2007-11-02 | 2015-09-08 | Massachusetts Inst Technology | métodos de conformidade de suplementação dietária de uridina e uso dos mesmos |
| WO2009057994A1 (en) | 2007-11-02 | 2009-05-07 | N.V. Nutricia | Unit dosage for brain health |
| ES2697149T3 (es) | 2007-12-20 | 2019-01-22 | Nutricia Nv | Producto líquido que contiene nucleótidos/nucleósidos |
| CA2751275A1 (en) * | 2009-02-02 | 2010-08-05 | Martek Biosciences Corporation | Use of docosahexaenoic acid in treating mild cognitive impairment |
| US8691775B2 (en) | 2010-04-19 | 2014-04-08 | Back Bay Scientific, Llc | Use of drugs that activate P2Y receptors to enhance synaptogenesis |
| WO2012125020A1 (en) | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| EP2806736A4 (en) * | 2011-10-21 | 2015-10-14 | Omthera Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF HYPERACTIVITY DISORDER WITH ATTENTION DEFICIT |
| WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| US20150044138A1 (en) * | 2012-03-02 | 2015-02-12 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| WO2013129914A1 (en) * | 2012-03-02 | 2013-09-06 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| WO2014171813A1 (en) | 2013-04-17 | 2014-10-23 | N.V. Nutricia | Nutritional composition for improving brain function in phenylketonuria |
| CN103877144B (zh) * | 2013-05-02 | 2017-02-22 | 杭州耐奇睿生物医药科技有限公司 | 花生衣活性组分的应用及包含该花生衣活性组分的组合物 |
| WO2015138879A1 (en) * | 2014-03-13 | 2015-09-17 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| WO2016083362A1 (en) * | 2014-11-25 | 2016-06-02 | Fonden For Helene Elsass Centeret | Composition for improving cognitive functions |
| WO2017069613A1 (en) | 2015-10-23 | 2017-04-27 | N.V. Nutricia | Method for improving recognition and/or working memory in hyperphenylalanimenia and phenylketonuria patients |
| WO2017155387A1 (en) * | 2016-03-08 | 2017-09-14 | N.V. Nutricia | Method for supporting memory function and/or cognitive function |
| SG11201803022TA (en) * | 2016-03-30 | 2018-05-30 | Nestec Sa | Compositions comprising fatty acids and their use |
| SG11201811595SA (en) * | 2016-06-27 | 2019-01-30 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| MX385552B (es) * | 2016-09-29 | 2025-03-18 | Soc Des Produits Nestle S A Star | Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia. |
| WO2018108976A1 (en) * | 2016-12-13 | 2018-06-21 | Dsm Ip Assets B.V. | Pufa salt formulations (ii) |
| WO2021231566A1 (en) * | 2020-05-12 | 2021-11-18 | Massachusetts Institute Of Technology | The use of choline supplementation as therapy for apoe4-related disorders |
| WO2022025785A1 (ru) | 2020-07-29 | 2022-02-03 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Фармацевтическая композиция, включающая мемантин и цитиколин |
| EP4353261A4 (en) * | 2021-06-09 | 2025-06-18 | Hospital Sant Joan de Deu | Nutraceutical combination and its use in the treatment of neurological diseases |
| CN113577092B (zh) * | 2021-07-30 | 2022-07-01 | 陈玉松 | 一种延缓衰老的含核苷酸的组合物及其制备方法和应用 |
| CN115774059A (zh) * | 2021-09-07 | 2023-03-10 | 中国科学院深圳先进技术研究院 | 一种阿尔兹海默症生物标志物及其筛选方法和应用 |
| TR2021016704A2 (tr) * | 2021-10-26 | 2021-11-22 | Bursa Uludag Ueniversitesi | Üri̇di̇ni̇n ön uyaran aracili i̇nhi̇bi̇syon bozukluğu i̇le seyreden hastaliklarin tedavi̇si̇nde kullanimi |
| WO2023150389A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Compositions and methods for increasing dha availability |
| CN115334384B (zh) | 2022-08-05 | 2025-03-14 | 立臻科技(昆山)有限公司 | 一种移动终端会议音箱 |
| CN119881117A (zh) * | 2023-10-25 | 2025-04-25 | 中国科学院上海营养与健康研究所 | 母乳芥酸检测在评价婴幼儿发育中的用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4221784A (en) * | 1979-04-05 | 1980-09-09 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering lecithin |
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
| US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| US20050027004A1 (en) | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| CA2164291C (en) * | 1993-06-09 | 2007-10-30 | David John Kyle | Methods and pharmaceutical compositions useful for treating neurological disorders |
| US5492899A (en) | 1994-01-10 | 1996-02-20 | Abbott Laboratories | Infant nutritional formula with ribo-nucleotides |
| JPH07143862A (ja) * | 1994-05-06 | 1995-06-06 | Maruha Corp | 脳機能改善効果を有する機能性食品。 |
| EP1886679A3 (en) * | 1995-06-07 | 2008-05-28 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
| JPH0975000A (ja) * | 1995-07-07 | 1997-03-25 | Nisshin Oil Mills Ltd:The | 母子栄養用油脂含有飲食物 |
| US6200624B1 (en) | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
| DE19608137A1 (de) * | 1996-03-02 | 1997-09-04 | Meyer Lucas Gmbh & Co | Lipid-Zubereitungen für diätetische Zwecke |
| JP3627043B2 (ja) | 1996-04-24 | 2005-03-09 | 明治乳業株式会社 | ｎ−６系列／ｎ−３系列脂肪酸バランス 改善ヌクレオチド含有乳児用食品 |
| DE69737063T2 (de) | 1996-07-23 | 2007-07-19 | Nagase Chemtex Corp. | Verfahren zur herstellung von decosahexaensäure und decosapentsäure |
| EP1039892B1 (en) | 1997-02-21 | 2004-04-28 | Abbott Laboratories | Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis |
| US6080787A (en) * | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
| JPH10327804A (ja) | 1997-06-04 | 1998-12-15 | Meiji Milk Prod Co Ltd | 核酸関連物質、ｄｈａ、アラキドン酸及び コレステロール含有栄養組成物 |
| JP3731983B2 (ja) | 1997-08-27 | 2006-01-05 | 明治製菓株式会社 | 痴呆犬の夜鳴き改善薬 |
| JP3408958B2 (ja) * | 1997-10-24 | 2003-05-19 | 旭化成株式会社 | 魚介類由来の有用物質を含む組成物およびその有用物質の製造方法 |
| US5977174A (en) * | 1997-11-26 | 1999-11-02 | Neuromedica, Inc. | Cholinergic compositions and uses thereof |
| US7413759B2 (en) | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
| US20050203053A1 (en) † | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| DK1140104T3 (da) * | 1998-07-31 | 2008-01-21 | Massachusetts Inst Technology | Behandling af Alzheimer's sygdom ved forögelse af cytidinniveauer in vivo |
| AU6384099A (en) | 1998-08-31 | 2000-03-21 | Proteotech, Inc. | Blended compositions for treatment of alzheimer's disease and other amyloidoses |
| US6472378B2 (en) * | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US6495599B2 (en) | 2000-04-13 | 2002-12-17 | Abbott Laboratories | Infant formulas containing long-chain polyunsaturated fatty acids and uses therof |
| US7226916B1 (en) * | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| CA2344564C (en) | 2000-09-14 | 2008-07-22 | General Electric Canada Inc. | Graded electric field insulation system for dynamoelectric machine |
| US6964969B2 (en) * | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
| GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
| JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| US6541043B2 (en) | 2001-08-28 | 2003-04-01 | Dexgen Pharmaceuticals, Inc. | Method and synergistic composition for treating attention deficit/hyperactivity disorder |
| EP1302196A1 (de) | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Intelligenzfördernde Zahncreme |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| US6677470B2 (en) * | 2001-11-20 | 2004-01-13 | Natural Asa | Functional acylglycerides |
| US20030114415A1 (en) * | 2001-12-14 | 2003-06-19 | Wurtman Richard J. | Compositions and methods for treating and preventing memory impairment using citicoline |
| US20040048926A1 (en) | 2002-03-15 | 2004-03-11 | Hoffman Dennis Robert | Use of docosahexaenoic acid and arachidonic acid to enhance the visual development of term infants breast-fed up to the age of six months |
| JP4771697B2 (ja) * | 2002-09-24 | 2011-09-14 | サントリーホールディングス株式会社 | 認知能力の正常応答の低下予防、改善又は向上作用を有する組成物 |
| JP2004231585A (ja) | 2002-12-05 | 2004-08-19 | Fancl Corp | 生体内ホモシステインレベル低減用および上昇抑制用組成物 |
| JP4717444B2 (ja) * | 2002-12-20 | 2011-07-06 | ザ マクレーン ホスピタル コーポレーション | 睡眠／覚醒サイクルの正規化のための化合物 |
| CN1203867C (zh) | 2003-03-11 | 2005-06-01 | 刘威 | 精制海狗油在制备防治老年痴呆药中的应用 |
| US7951410B2 (en) | 2003-04-14 | 2011-05-31 | Mead Johnson Nutrition Company | Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid |
| US7867541B2 (en) | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
| BRPI0414818A (pt) | 2003-09-26 | 2006-11-14 | Nestec Sa | composição nutricional com ácidos graxos insaturados e elementos traço |
| US8921422B2 (en) | 2003-10-01 | 2014-12-30 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
| US20050129710A1 (en) | 2003-10-08 | 2005-06-16 | Renshaw Perry F. | Methods of treating psychiatric substance abuse, and other disorders using combinations containing omega-3 fatty acids |
| EP1634599A1 (en) | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Iimmune stimulatory infant nutrition |
| EP1656839A1 (en) | 2004-11-11 | 2006-05-17 | N.V. Nutricia | Nutrition containing lipid blend |
| US20060247153A1 (en) | 2005-04-29 | 2006-11-02 | Mcmahon Robert J | Method of improving learning and memory in mammals |
| EP1888081B1 (en) * | 2005-05-23 | 2016-12-28 | Massachusetts Institute of Technology | Compositions containing pufa and methods of use thereof |
| US7829126B2 (en) | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
-
2006
- 2006-05-23 EP EP06770862.8A patent/EP1888081B1/en active Active
- 2006-05-23 CA CA2645645A patent/CA2645645C/en active Active
- 2006-05-23 AU AU2006251569A patent/AU2006251569B2/en active Active
- 2006-05-23 NZ NZ563659A patent/NZ563659A/en active IP Right Revival
- 2006-05-23 JP JP2008513592A patent/JP5566603B2/ja active Active
- 2006-05-23 NZ NZ563660A patent/NZ563660A/xx unknown
- 2006-05-23 AU AU2006251562A patent/AU2006251562B2/en active Active
- 2006-05-23 ES ES06770862.8T patent/ES2615521T3/es active Active
- 2006-05-23 PL PL06770862T patent/PL1888081T3/pl unknown
- 2006-05-23 DK DK06770862.8T patent/DK1888081T3/en active
- 2006-05-23 NZ NZ600740A patent/NZ600740A/en unknown
- 2006-05-23 CA CA2645647A patent/CA2645647C/en active Active
- 2006-05-23 WO PCT/US2006/019778 patent/WO2006127627A2/en not_active Ceased
- 2006-05-23 JP JP2008513596A patent/JP5566604B2/ja not_active Expired - Fee Related
- 2006-05-23 HU HUE06770862A patent/HUE031206T2/en unknown
- 2006-05-23 PT PT67708628T patent/PT1888081T/pt unknown
- 2006-05-23 EP EP06770871.9A patent/EP1909801B2/en active Active
- 2006-05-23 US US11/920,915 patent/US10086009B2/en active Active
- 2006-05-23 BR BRPI0613303A patent/BRPI0613303A8/pt not_active Application Discontinuation
- 2006-05-23 US US11/920,914 patent/US10525071B2/en active Active
- 2006-05-23 EP EP16171448.0A patent/EP3090740A1/en not_active Withdrawn
- 2006-05-23 ES ES06770871T patent/ES2624702T5/es active Active
- 2006-05-23 BR BRPI0613274-0A patent/BRPI0613274A2/pt not_active Application Discontinuation
- 2006-05-23 CN CN201610212919.6A patent/CN105663151A/zh active Pending
- 2006-05-23 WO PCT/US2006/019766 patent/WO2006127620A2/en not_active Ceased
-
2011
- 2011-05-20 RU RU2011120440/15A patent/RU2603470C2/ru active
-
2014
- 2014-04-23 JP JP2014088988A patent/JP5823564B2/ja active Active
-
2018
- 2018-10-01 US US16/148,546 patent/US10736912B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2615521T3 (es) | Composiciones que contienen PUFA y métodos de uso de las mismas | |
| US11135230B2 (en) | Lipid compositions with high DHA content | |
| Kennedy | The biosynthesis of phospholipids | |
| Anderson et al. | Can prenatal N-3 fatty acid deficiency be completely reversed after birth? Effects on retinal and brain biochemistry and visual function in rhesus monkeys | |
| Epstein et al. | The choline incorporation pathway: Primary mechanism for de novo lecithin synthesis in fetal primate lung | |
| ES3007832T3 (en) | Nutritional product comprising decanonic acid and octanoic acid | |
| Ansell et al. | Plasmalogenase activity in normal and demyelinating tissue of the central nervous system | |
| Bleasdale et al. | Inositol and phosphoinositides: metabolism and regulation | |
| Uauy et al. | Lipids and neurodevelopment/Discussion/Comment | |
| Wang et al. | The bioactive of four dietary sources phospholipids on heavy metal-induced skeletal muscle injury in zebrafish: A comparison of phospholipid profiles | |
| López-Rios et al. | Toxicological assessment of Xanthigen® nutraceutical extract combination: Mutagenicity, genotoxicity and oral toxicity | |
| JP2005525335A (ja) | Ｎ−アシル−ホスファチジル−エタノールアミン類及び／又はｎ−アシル−エタノールアミン類とホスファチジン酸類又はリゾホスファチジン酸類との混合物 | |
| AU2012337087B2 (en) | Therapeutic agent for arthrosis | |
| Neuschwander-Tetri | Betaine: an old therapy for a new scourge | |
| Gross | The hormonal regulation of fetal lung maturation | |
| Francescangeli et al. | THE METABOLISM OF LABELLED CHOLINE IN NEURONAL AND GLIAL CELLS OF THE RABBIT IN VIVO 1 | |
| DE102011105703A1 (de) | Diätetikum zur Behandlung mitochondrialer Dysfunktionen | |
| CN106074577A (zh) | 用于改善记忆力的功能型营养组合物及其应用 | |
| JP2015507642A (ja) | 健康の維持ならびに急性および慢性障害の治療のための脂質サプリメントを含有するチュアブルウエハース | |
| Valenzuela et al. | Supplementing female rats with DHA-lysophosphatidylcholine increases docosahexaenoic acid and acetylcholine contents in the brain and improves the memory and learning capabilities of the pups. | |
| IT8922173A1 (it) | Composizioni farmaceutiche a base di l-alfa-glicerofosforil-d-myo- inositolo o suoi sali alcalini o alcalino-terrosi per la terapia delle neuropatie periferiche di origine dismetabolica o tossica, e delle cerebropatie su base organica e funzionale | |
| Granata et al. | Phosphocholine and phosphoethanolamine during chick embryo myogenesis: a 31P-NMR study | |
| Bazan | The supply of omega-3 polyunsaturated fatty acids to photoreceptors and synapses | |
| Cherniaeva et al. | Lipidome Alterations in Brain and Blood Plasma in Rats with Sciatic Nerve Injury | |
| Sourkes | Social and medical origins of neurochemistry |